Table 1.
Dex group (n = 25) | Control group (n = 25) | |
Age (years) | 68.4 ± 6.4 | 69.4 ± 8.7 |
Sex (M/F) | 12/13 | 11/14 |
Height (cm) | 162.9 ± 6.9 | 162.3 ± 8.4 |
Weight (kg) | 60.8 ± 8.9 | 61.3 ± 8.9 |
BMI (kg m−2) | 22.3 ± 2.7 | 22.7 ± 2.1 |
ASA physical status, 2/3 | 11/14 | 12/3 |
Hypertension | 10 | 11 |
Cardiovascular medication | ||
RAAS inhibitor | 8 | 8 |
Calcium channel blocker | 1 | 2 |
β-adrenergic antagonists | 0 | 1 |
Furosemide | 2 | 2 |
Smoking | ||
Ex-smoker/current smoker | 11/12 | 14/10 |
Smoking index, pack-years | 36.7 ± 27.1 | 35.8 ± 28.9 |
Non-smoker | 2 | 1 |
Medication | ||
Inhaled corticosteroid | 42.7% | 39.5% |
Oral corticosteroid | 18.6% | 14.3% |
Inhaled bronchodilator | 21.3% | 17.9% |
Oral bronchodilator | 33.6% | 34.2% |
Muscarinic antagonists | 3.7% | 3.2% |
Preoperative SpO2, % | 93.8 ± 1.2 | 94.1 ± 1.3 |
Preoperative spirometry | ||
FEV1, % predicted | 60.8 ± 5.2 | 61.4 ± 4.1 |
FVC, % predicted | 82.7 ± 8.6 | 83.1 ± 7.2 |
FEV1/FVC, % | 55.9 ± 3.2 | 56.1 ± 5.7 |
FEF25–75%, l s−1 | 26.4 ± 18.9 | 27.1 ± 19.3 |
FEF50%, l s−1 | 18.9 ± 11.3 | 19.3 ± 12.7 |
DLco, % predicted | 93.6 ± 8.2 | 92.3 ± 7.6 |
Intraoperative data | ||
Anaesthesia time (min) | 193.6 ± 24.6 | 189.7 ± 44.1 |
Operation time (min) | 163.8 ± 39.4 | 158.1 ± 33.2 |
OLV time (min) | 125.6 ± 37.1 | 124.7 ± 41.2 |
Fluid intake (ml) | 791.4 ± 92.3 | 813.2 ± 79.5 |
Urine output (ml) | 274.5 ± 132.6 | 354.6 ± 132.7 |
Estimated blood loss (ml) | 122.4 ± 55.6 | 125.6 ± 84.7 |
Number receiving ephedrine | 9* | 1 |
Right/left lobectomy | 17/8 | 16/9 |
Right upper lobe | 8 | 5 |
Right middle lobe | 2 | 5 |
Right lower lobe | 7 | 6 |
Left upper lobe | 4 | 6 |
Left lower lobe | 4 | 3 |
Values are mean ± SD, number or percentage of patients. ASA, American Society of Anesthesiologists; DLco, diffusion capacity of lung for carbon monoxide; FEF25–75%, forced expiratory volume between 25 and 75% of the FVC; FEF50%, forced expiratory volume 50% of the FVC; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; OLV, one-lung ventilation; RAAS, renin–angiotensin–aldosterone system; SpO2, oxygen saturation (pulse oximetry).
*P < 0.05 vs. control group.